Across TCGA pan-cancer cohorts, C16orf96 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated C16orf96 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher C16orf96 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C16orf96 expression acts as an unfavorable survival marker, although some lineages such as LIHC show a favorable association.

STAD, UCEC, and ESCA are the cancer types where C16orf96 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.183	0.677	.004	24	view →
UCEC	OS	Median	IV	0.195	0.799	<.001	12	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →
LIHC	DFS	Median	II,III,IV	1.000	0.198	.039	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: C16orf96 tumor-vs-normal RNA expression · all C16orf96 data types